Could a blood pressure drug slow Alzheimer's? new trial aims to find out
NCT ID NCT06362707
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial tests whether fasudil, a drug already used in Japan and China for brain blood vessel spasms, can improve memory and brain function in people with early Alzheimer's disease. Two hundred participants will receive either fasudil or a placebo for 12 months, with regular cognitive tests and brain scans to measure effects. The goal is to see if fasudil can slow the decline in thinking skills and brain metabolism.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Fasudil (a drug approved in Japan and China for vasospasms, now being tested for Alzheimer's)
What this could lead to
If it works, this could point toward a treatment that slows memory loss and brain decline in early Alzheimer's disease.
What could go wrong
This is an early Phase 2 trial with only 200 participants, so results may not apply to everyone. The drug is not yet proven for Alzheimer's, and side effects are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Akershus Hospital:
NOT_YET_RECRUITINGOslo, Oslo, Norway
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Haraldsplass Deaconess Hospital
ENROLLING_BY_INVITATIONBergen, Vestland, Norway
-
Haugesund Hospital
NOT_YET_RECRUITINGHaugesund, Rogaland, Norway
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
St. Olavs Hospital:
NOT_YET_RECRUITINGTrondheim, Trøndelag, Norway
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Stavanger University Hospital
RECRUITINGStavanger, Rogaland, Norway
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
-
University Hospital of North Norway
NOT_YET_RECRUITINGTromsø, Nordland, Norway
Contact Phone: •••-•••-•••• Email: •••••@•••••